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The aim of this study was to assess the immune modulatory properties of human mesenchymal stromal cells
obtained from bone marrow (BM-MSCs), fat (ASCs), and cord blood (CB-MSCs) in the presence of a hy-
droxyapatite and tricalcium-phosphate (HA/TCP) biomaterial as a scaffold for MSC delivery. In resting con-
ditions, a short-term culture with HA/TCP did not modulate the anti-apoptotic and suppressive features of the
various MSC types toward T, B, and NK cells; in addition, when primed with inflammatory cytokines, MSCs
similarly increased their suppressive capacities in the presence or absence of HA/TCP. The long-term culture of
BM-MSCs with HA/TCP induced an osteoblast-like phenotype with upregulation of OSTERIX and OSTEO-
CALCIN, similar to what was obtained with dexamethasone and, to a higher extent, with bone morphogenetic
protein 4 (BMP-4) treatment. MSC-derived osteoblasts did not trigger immune cell activation, but were less
efficient than undifferentiated MSCs in inhibiting stimulated T and NK cells. Interestingly, their suppressive
machinery included not only the activation of indoleamine-2,3 dioxygenase (IDO), which plays a central role in
T-cell inhibition, but also cyclooxygenase-2 (COX-2) that was not significantly involved in the immune
modulatory effect of human undifferentiated MSCs. Since COX-2 is significantly involved in bone healing, its
induction by HA/TCP could also contribute to the therapeutic activity of MSCs for bone tissue engineering.
Introduction
Bone has been considered a metabolically inert tissuefor a long time; actually, in adult vertebrates, it is re-
modeled so significantly that *10% of the total bone con-
tent is replaced every year.1 Bone remodeling is dependent
on the dynamic balance between bone formation and re-
sorption, which are mediated by osteoblasts and osteoclasts,
respectively.2
The process of bone formation, namely osteogenesis,
continues throughout the adult life as bone remodeling and is
re-activated during fracture healing.3 A fine regulation of this
process is a prerequisite for normal bone homeostasis: Its
imbalance is often linked to traumatic events or metabolic
bone diseases, such as nonunion of large bone fractures or
excessive bone resorption related to inflammatory bone loss.4
Bone regeneration may be impaired even in the absence
of specific disease; for instance, 13% of tibia fractures are
associated with delayed union or nonunion.5 In addition,
other conditions in orthopedic and maxillofacial surgery
require a more extensive bone regeneration that the normal
self-healing cannot provide; among them are the skeletal
reconstruction of large bone defects related to trauma, in-
fections, tumor resection, and skeletal abnormalities, or
conditions in which the regenerative process is compro-
mised, such as avascular necrosis and osteoporosis.6
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Autologous bone grafting is the most common method
used to treat critical-sized bone defects.7 Bone grafts fill
empty spaces and provide support to enhance the biological
repair of the defect. The need for bone harvesting, which is a
painful procedure associated with significant morbidity, is
the main drawback of this method.8,9 Therefore, alternative
approaches of tissue engineering and new scaffolds have
been developed to support bone regeneration and avoid
autologous bone grafting. Indeed, bone tissue engineering
(BTE) is based on the use of novel devices developed in
consideration of important concepts related to bone com-
position and functions.10
Since the beginning of the 21st century, natural and
synthetic polymers have been enriched with osteogenic
factors to improve their mere filler properties. Bioactive
factors, including bone morphogenetic proteins (BMP-2,
BMP-3, BMP-4, and BMP-7), vascular endothelial growth
factor (VEGF), or basic fibroblast growth factor, were used
in different experimental settings in animal models.10–12
Collagen sponges containing recombinant human BMP-2
(INFUSE; Bone Graft, Medtronic, Minneapolis, MN) are
approved for clinical use in the United States, and bovine
collagen containing recombinant human BMP-7 (Osigraft;
Olympus Biotech Corporation, West Lebanon, NH) has
been approved by European Medicine Agency (EMA) for
clinical use in Europe. The most common ceramics used in
BTE include calcium sulfate and calcium phosphate, such as
hydroxyapatite (HA) and b-tricalcium phosphate (b-TCP).
HA and b-TCP have been approved in dental implants since
the mid-1980s and are now approved for use in orthopedic
implants and as bone substitutes.
BTE methods may be further improved by the employ-
ment of ex vivo expanded stem cells, which represent a very
helpful alternative to overcome the drawbacks related to
bone autograft and the use of biomaterials. In this field,
mesenchymal stromal cells (MSCs) are considered a
promising tool for cell therapy in regenerative medicine and
for prevention or treatment of severe inflammatory and
autoimmune diseases.13 MSCs possess peculiar and multi-
faceted immune regulatory properties.14–17 So far, the po-
tential therapeutic application of MSCs for regenerative
medicine and autoimmune diseases has been tested in var-
ious animal models, and it is currently under evaluation in
humans. Encouraging results have been recently reported in
steroid-resistant graft-versus-host disease, Crohn’s disease,
multiple sclerosis, kidney transplant rejection, and long
bone nonunions.18–22
Although some reports described the role of the three-
dimensional structure of biomaterials as a key regulator of
MSC differentiation potential,23,24 little data have been pub-
lished on the effects of the scaffold on the MSC-mediated
modulation of immune effector cells, particularly in view of
allogeneic stem cell-based therapeutic strategies. Recent re-
ports have focused on the capability of some biomaterials to
interfere both in vitro and in vivo with the immune system
functions, but these studies essentially relied on nonspecific
assays targeting innate immunity.25,26 Different groups
worldwide have studied the immunosuppressive activity of
MSCs and their anti-apoptotic effect toward various cell
types, such as hematopoietic- and solid-tumor cell lines.
Nevertheless, there is significant discrepancy in published
data, mainly because of the lack of an international consensus
on experimental conditions, procedures, and models used by
different groups.27–30 Thus, to understand whether hydroxy-
apatite and tricalcium-phosphate (HA/TCP) could modulate
immune cell activation and survival, we used a panel of inter-
laboratory standardized assays to study the behavior of im-
mune cells in contact with the scaffold.31
A novel biomaterial composed of HA/TCP (microporous
biphasic calcium phosphate [MBCP]; Biomatlante SA,
Vigneux-de-Bretagne, France) has been evaluated inside the
REBORNE (Regenerating Bone defects using New bio-
medical Engineering approaches) European consortium
(FP7-HEALTH-241879) as a suitable candidate for MSC-
based BTE. Hence, we assessed the changes of immune
modulatory properties, in terms of immunophenotype, sup-
pressive, and anti-apoptotic effects of MSCs from different
origin; that is, bone marrow (BM-MSCs), adipose-tissue
(ASCs), and cord blood (CB-MSCs), growing in contact
with HA/TCP scaffold. Moreover, we compared in different
MSC types the capability of BMP-4 and dexamethasone
(DXM), in the presence or absence of HA/TCP, to induce
the osteoblast-like phenotype and immunomodulatory func-
tions toward both innate and adaptive immune cells. Alto-
gether, our data may be useful to the application of MSCs
plus HA/TCP scaffold for advanced therapies of BTE in
allogeneic settings.
Materials and Methods
Cell culture
Clinical-grade BM-MSCs, ASCs, and CB-MSCs were
obtained in three hospital-based GMP facilities, according to
standardized protocols, from healthy donors after written in-
formed consent. Briefly, for BM-MSC isolation (n= 5), whole
BM was plated at 50,000 nucleated cells per cm2 in closed
cell culture devices (CellSTACK; Corning, Lowel, MA).
Adherent cells were ex vivo expanded in a-minimum essential
medium (a-MEM) culture medium supplemented with 5%
(passage 0) and 8% (passage 1) platelet lysate (PL, Institut fu¨r
Klinische Transfusionsmedizin und Immungenetik, Ulm,
Germany) and 2 IU/mL heparin (Braun, Melsungen, Ger-
many) as previously described.32 ASCs (n= 5) were obtained
from lipo-aspirates that were enzymatically digested to obtain
a single-cell suspension and plated at 50,000 nucleated cells
per cm2 in CellSTACK devices containing a-MEM culture
medium supplemented with 2% apheresis-derived clinical-
grade PL and 2 IU/mL heparin. CB-MSCs (n= 4) were iso-
lated from whole CB samples by plating cells at 50,000/cm2
in CellSTACK devices containing SPE-IV (ABCell-Bio;
BIOSPA, Milano, Italy) culture medium supplemented with
10% fetal bovine serum (FBS; Gibco, Life Technologies,
Milan, Italy). All the MSC types could be induced to differ-
entiate into osteoblastic, chondrocytic, and adipocytic line-
ages and were negative for bacterial contamination; in
addition, they lacked hematopoietic and endothelial marker
expression (< 2% cells positive for CD45, CD14, and CD31),
as assessed by flow cytometry, and constantly expressed
MHC-class I molecules and classical mesenchymal markers
(> 90% HLA-ABC-, CD73-, CD90-, and CD105-positive
cells). After 10–14 days at passage 0, MSCs were trypsinized,
further expanded, and frozen at the end of passage 1 to pas-
sage 3. BM-MSCs, ASCs, and CB-MSCs were thawed and
plated at 1000 cells per cm2 in the same medium used during
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the ex vivo expansion and cultured until *80% confluence
was reached. Then, MSCs were harvested and re-seeded in
parallel both in tissue culture plates and onto HA/TCP discs.
HA/TCP formulation for clinical use consists of granules; to
carry out the in vitro experiments with a standardized ap-
proach, we used some discs, obtained by mechanical pressure
of the HA/TCP granules, of the diameter fitting with the wells
of 24-well plates. HA/TCP ceramic discs (Micro-macro-
porous Biphasic Calcium Phosphate, MBCP+, CE mark,
and FDA approval) were provided by Biomatlante SA.
The HA/TCP discs are composed of HA/TCP in a 20/80
ratio according to X-ray diffraction (Rigaku Miniflex, CuK-
a source). No impurities such as carbonates were detected
by Fourier transformed infrared spectroscopy (Nicolet,
Magnia 550). The surface morphology of the material was
evaluated on samples sputter coated with gold palladium
using scanning electron microscopy (LEO 1450 VP).
HA/TCP discs were inserted in ultra-low-attachment 24-
well plates (Corning) to avoid attachment of MSCs to the
well bottom. Briefly, after the detoxification of the bioma-
terial through replacement of culture media every 12 h for 2
days, MSCs were resuspended at 1 · 106/mL concentration
and 200mL of cell suspension was added to each well
containing HA/TCP disc. For standard culture setting, 104
MSCs were seeded in 96-well flat-bottom plates. The dif-
ferences in cell number between standard and HA/TCP
culture conditions are related to the technical need to
guarantee the same MSC/effector cell ratios regardless of
the well size of culture plates. In this way, the same cell
density per cm2 was used in all culture conditions.
After a 5-day culture, half of the wells were exposed for
48 h to 10 ng/mL interferon-g (IFN-g) and 15 ng/mL tumor
necrosis factor-a (TNF-a) (R&D Systems, Abington, United
Kingdom) for inflammatory priming. Then, cells were
trypsinized and harvested for subsequent phenotypic anal-
ysis. For co-culture experiments, MSCs were extensively
washed with phosphate-buffered saline (PBS) to completely
remove cytokines before the addition of immune cells.
Immunological phenotypic study
Unprimed and primed MSCs at passage 4 were assessed
for the expression of various markers involved in cross-talk
with immune cells: antigen presentation molecules HLA-
ABC and CD86 from Becton Dickinson (Franklin Lakes, NJ);
HLA-DR and CD80, from Beckman Coulter; and cell adhe-
sion molecules CD54 and CD106, from Becton Dickinson.
MSCs cultured on HA/TCP scaffold were harvested through
repeated trypsin treatments. Trypsin activity was inhibited at
the end of each cycle by adding complete culture medium.
The presence of a single-cell suspension was confirmed by
microscope visualization and by using forward scatter-height
versus forward scatter-area to exclude doublets during fluo-
rescence-activated cell sorting (FACS) analysis. In addition,
the persistence of adherent MSCs to the biomaterial following
the harvesting process was excluded by microscopy (Zeiss,
Observer Z1). Two hundred thousand MSCs were pelleted,
resuspended, and incubated with conjugated monoclonal an-
tibody, following the manufacturer’s instructions, for 15min
at room temperature. Then, cells were washed and analyzed
by FACS Canto (Becton Dickinson) after additional TO-
PRO-3 (Life Technologies) staining. A restricted phenotype
(CD54, CD106, HLA-ABC, and HLA-DR expression) was
used to compare the immunological phenotype of MSCs in
the presence or absence of HA/TCP biomaterial. Expression
was quantified as relative mean fluorescence intensi-
ty– standard error of the mean (rMFI–SEM).
Immunological assays
Immunological assays were performed as previously
standardized.31 Buffy coats were obtained from Transfusion
Center (AOUI, Verona, Italy) and processed to obtain pe-
ripheral blood mononuclear cells (PBMC, n = 15). Then, T,
B, or NK cells were purified by negative selection with
magnetic beads (magnetic activating cell sorting; Miltenyi
Biotec, Cologne, Germany), following the manufacturer’s
instructions. Only products with purity > 95% and viability
> 98% were cryopreserved and used for subsequent exper-
iments. Both MSC cell batch and immune effector cell
variability were considered, and the immunomodulatory
properties of MSCs were tested on a number of PBMC
donors (n = 15) to obtain consistent data. Thawed T (n= 5),
B (n = 5), and NK (n= 5) cells were resuspended in appro-
priated culture medium. For T cells, RPMI 1640 (Gibco,
Life Technologies) was supplemented with 10% Human AB
Serum (Institut Jacques Boy, Reims, France); for B cells,
RPMI 1640 was supplemented with 10% Australian-
selected FBS (Gibco, Life Technologies); and for NK cells,
IMDM (Gibco, Life Technologies) was supplemented with
10% Human AB Serum.
T,- B-, and NK-cell proliferation was assessed with car-
boxyfluorescein-diacetate-succimidyl-ester method (CFSE;
Gibco, Life Technologies). CFSE-labeled cells were seeded
on MSCs at passage 4 and were previously plated in 96-well
flat-bottom plates or in 24-well ultra-low attachment
plates+HA/TCP, at different ratios (10:1 for T:MSCs, 1:1 for
NK:MSCs and B:MSCs). Then, nonantigen-specific stimuli
were added to culture to address the effect of MSCs on the
different immune effector cell proliferation. T cells were
activated with 0.5mg/mL cross-linking anti-CD3 and anti-
CD28 antibodies (Sanquin, Amsterdam, The Netherlands) for
6 days. B cells were activated with 2mg/mL F(ab¢)2 anti-
human IgM/IgA/IgG antibody (Jackson Immunoresearch,
Suffolk, United Kingdom), 50 IU/mL interleukin-2 (IL-2,
Proleukin; Novartis, Basel, Switzerland), 0.5mg/mL poly-
histidine-tagged CD40 ligand, 5mg/mL anti-polyhistidine
cross-linking antibody (R&D Systems), and 0.5mg/mL CpG
B (ODN 2006; Invivogen, Toulouse, France) for 4 days. NK
cells were activated with 100 IU/mL IL-2 for 6 days. At the
end of co-culture, cells were trypsinized, stained with TO-
PRO-3 (Life Technologies), CD45-PerCP (Beckton Dick-
inson), and acquired by a flow cytometer. Proliferation was
assessed by CFSE dilution of CD45+ cells using FlowJo
software (TreeStars, La Jolla, CA), and percentage of viable
cells undergoing more than one cell division was considered
for quantification of immunosuppressive properties of MSCs
by means of the following formula: percentage of inhibition
of proliferation= (percentage proliferation of lymphocytes
without MSCs- percentage proliferation of lymphocytes with
MSCs)/(percentage proliferation of lymphocytes without
MSCs)*100.
In some experiments, specific inhibitors of immunosup-
pressive molecular pathways were added to MSC/T cell
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coculture, that is, 1mM L-1-methyltryptophan (L-1MT;
Sigma-Aldrich, Milan, Italy), 5mM NS-398 (Cayman Che-
micals, Ann Arbor, MI), and 10mg/mL of IFN-g blocking
antibody (Becton Dickinson).
To determine the anti-apoptotic features of MSCs, un-
stimulated lymphocytes were seeded either alone or at dif-
ferent ratios with BM-MSCs, ASCs, and CB-MSCs. T cells
were co-cultured at a T:MSC ratio of 10:1, while B and NK
cells were cocultured at 1:1 (B or NK:MSC). After 4 days
(B and NK cells) or 6 days (T cells) of co-culture, cells were
harvested by trypsinization and stained with CD45-APC
antibody (Becton Dickinson). After centrifugation, the su-
pernatant was discarded and the cell pellet was fixed with
CytoFix/CytoPerm (Becton Dickinson) for 20min at 4C.
Then, cells were washed with Perm&Wash Buffer (Becton
Dickinson), stained with anti-active-caspase-3-PE (Becton
Dickinson), and analyzed by flow cytometry.
Osteogenic differentiation
Sub-confluent BM-MSCs, ASCs, and CB-MSCs cultured
in 24-well plates with or without HA/TCP discs were treated
for 21 days with osteogenic medium. Two differentiation
media were tested, both of which contained not only a
common osteogenic cocktail including a-MEM, 2% FBS,
1mM b-glycerophosphate (Sigma-Aldrich), and 50 mM
ascorbic acid, but also either 0.1 mM DXM (Sigma-Aldrich)
or 50 ng/mL BMP-4 (R&D System). Differentiation media
were replaced twice a week. At the end of culture, some
wells were selected for the immunological studies previ-
ously described, by using the same immune cell batches.
Supernatants were stored at - 20C to assess cytokine pro-
duction and tryptophan/kynurenin ratio, as previously de-
scribed.31 Other wells were treated with Trizol Reagent
(Invitrogen, Life Technologies, Torino, Italy) for RNA
extraction and quantitative real-time polymerase chain re-
action (RT-qPCR). Some other wells were selected for
colorimetric assays to confirm the differentiation of cultured
cells, including alkaline phosphatase (ALP), Alizarin Red
(AR) staining, and Von Kossa (VK) staining. Briefly, cells
were fixed with 4% paraformaldehyde (Sigma-Aldrich) for
30 s at room temperature. Then, for ALP staining, a solution
containing New Fucsin (Sigma-Aldrich) in Propanediol
buffer supplemented with naphtol-ASBI-phosphate (Sigma-
Aldrich) was added to wells, incubated for 30min under
stirring, and washed thrice with PBS. For AR staining, cells
were incubated for 10min with AR solution under stirring
(AR 2%, pH 4.1) and washed thrice with deionized water to
remove unspecific staining. For VK staining, cells were
exposed to light for 1 h in the presence of 10% solution of
silver nitrate (Sigma-Aldrich). After washing with deionized
water, the wells were incubated with sodium thiosulfate
solution 10% (Sigma-Aldrich) for 5min. Stained cells were
acquired by an inverted microscope (Zeiss, Observer Z.1) at
10 · magnification.
Quantitative PCR
Cells were lysed using Trizol reagent (Life Technologies),
and RNA was extracted following the manufacturer’s pro-
tocol. Total RNA (2mg) was then cleaned up using RNeasy
Mini kit (Qiagen, Limburg, The Netherlands) to discard
DNA and solvent contamination according to RNA clean-up
protocol. RNA purity and integrity was checked using the
Experion RNA Std Sens Reagents on the Experion au-
tomatized system (Bio-Rad, Hercules, CA). All samples used
for cDNA synthesis displayed an RNA integrity number
above 9. Whole purified RNA was then reverse transcribed
by the PrimeScript RT-PCR kit (Takara Bio, Inc., Otsu,
Japan). Quantitative PCR was performed on diluted cDNA
(equivalent to 25 ng of starting purified RNA) using SSoFast
EvaGreen Supermix (Bio-Rad) with 500 nM of forward and
reverse primers in a total volume of 20mL on a CFX Real
Time System (Bio-Rad) as follows: 95C, 3min, and 40
cycles of denaturation (95C, 10 s) and primers hybridation
and amplification (60C, 30 s). Primer sequences are listed in
Supplementary Table S1 (Supplementary Data are available
online at www.liebertpub.com/tea).
Each primer couple displayed interpretable PCR effi-
ciency (95–105%). Melt curves and appropriate controls
were used to validate amplification specificity. Data were
analyzed on Bio-Rad CFX manager (threshold = 0.2) and
exported to DataAssist Software v3.0 (Applied Biosystems,
Foster City, CA). Gene expression was calculated using the
fold change of 2-DDCt method using GAPDH as an appro-
priate reference gene with the smallest M score.
Western blotting
For total protein lysate, cells were lysed with sodium
deoxycholate (DOC) 5% w/v (Calbiochem, Billerica, MA)
in ddH2O supplemented with Complete Protease Inhibitor
(Sigma-Aldrich). In order to quantify protein lysate, the
BCA protein assay kit (Bicinchoninic Acid Assay, Thermo
Scientific, Waltham, MA) was used according to the man-
ufacturer’s instructions. Then, 20 mg of protein lysate were
resolved by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE), and blotted on a 0.45 mm ni-
trocellulose filter for further analysis.
Anti-RunX2, anti-NF-kB, anti-phospho-NF-kB, and anti-
phospho-Smad-1, -5, and -8 (all from Cell Signaling, Dan-
vers, MA) were used at 1:5000 dilution; instead, b-actin
(Sigma-Aldrich) was used at 1:30,000 dilution. Secondary
antibodies were anti-mouse, anti-goat (both from Sigma-
Aldrich), and anti-rabbit (GE Healthcare, Pittsburgh, PA)
labeled with ALP or horseradish peroxidase, all of which
were used at 1:10,000 working dilution.
For quantification of RunX2 expression, relative protein
level was referred to b-actin using Imagej densitometric
software plugins.
Results
Lymphocyte behavior and MSC phenotype
in presence of HA/TCP
We analyzed the survival of unstimulated purified T, B,
and NK cells after 4–6 days of co-culture with HA/TCP discs.
As shown in Figure 1A, lymphocyte spontaneous apoptosis
rate was not modified by the presence of biomaterial. More-
over, neither cell activation nor proliferation of unstimulated
CFSE-labeled immune cells was observed (data not shown).
Similarly, HA/TCP discs did not modify immune cell pro-
liferation, as assessed by comparing the percentage of cells
undergoing at least one division with or without HA/TCP
(Fig. 1B). These data confirm previous reports on the
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biocompatibility of HA/TCP materials and foster their use-
fulness as a bone defect filler in clinical practice.
Then, we asked whether the presence of HA/TCP could
affect the immunophenotypic pattern of MSCs of different
origins. First, we found that MSCs could be cultured without
alteration of cell growth in association with HA/TCP discs
and harvested at 7 days after culture. The selection of markers
was based according to the minimal criteria to define MSCs.33
As shown in Figure 1C, BM-MSCs expressed CD73, CD90,
and CD105, without any difference related to presence of the
scaffold. Similar marker expression was found in ASCs and
CB-MSCs (data not shown). We then analyzed the expression
of molecules related to the immunological behavior of MSCs
by studying in parallel the immune phenotype of both resting
(Fig. 1D) and IFN-g/TNF-a-primed MSCs (data not shown).
Even in the presence of biomaterial, all MSC types were
negative for the expression of CD80, CD86, and HLA-DR.
As expected, HLA-ABC molecules were always detected on
MSC surface at a different intensity depending on cell origin
and expansion medium employed (Table 1). CB-MSCs ex-
pressed a lower level of HLA-ABC in resting and primed
conditions, as compared with BM-MSCs or ASCs. ASCs and
CB-MSCs never expressed CD106 in resting conditions, but
it was de novo expressed after inflammatory priming and
could also be upregulated in BM-MSCs, thus confirming
previous data from our group.31 CD54 was already expressed,
regardless of the presence of HA/TCP and was induced after
inflammatory priming. Moreover, the upregulation of HLA-
ABC molecules and the de novo expression of HLA-DR were
also observed in BM-MSCs and ASCs even in contact with
biomaterial. CB-MSCs showed lower HLA-DR expression
after inflammatory priming, as compared with the other MSC
types. In summary, the association of MSCs with HA/TCP,
mimicking the natural composition of bone tissues, did not
significantly modify the expression of immunological mark-
ers on MSCs.
Anti-apoptotic and immune modulatory properties
of BM-MSCs, ASCs, and CB-MSCs in presence
of HA/TCP scaffold
We compared the survival of immune effector cells in co-
culture with different MSC types in the absence or presence
of HA/TCP scaffold. As shown in Figure 2A, the combina-
tion of BM-MSCs, ASCs, and CB-MSCs with HA/TCP did
not affect their anti-apoptotic properties toward lympho-
cytes. Co-culture with all MSC types significantly increased
B- and NK-cell survival, regardless of the presence of the
FIG. 1. Effect of hydroxyapatite (HA)/tricalcium-phosphate (TCP) discs on survival and proliferation of T, B, and NK
cells. (A) Relative percentage of live (CD45+ /active-caspase 3- ) and dead cells (CD45 + /active-caspase 3 + ) after culture in
absence or presence of HA/TCP discs (n = 8); (B) Percentage of live CFSE-labeled dividing cells after 4–6 days of culture
in absence or presence of HA/TCP (n = 8); (C) mesenchymal stromal cells (MSCs) were collected after 5 days of culture in
absence or presence of HA/TCP and stained with appropriate antibodies (empty histogram) or isotype-matched controls
(gray histogram). One bone marrow (BM)-MSC sample, representative of 14 MSC batches (5 BM-MSCs, 5 ASCs, and 4
cord blood [CB]-MSCs), is shown for MSC-related markers and, in (D), for immunological markers. Wilcoxon paired test
was used to compare different groups, ns p > 0.05.
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HA/TCP scaffold. As expected, T-cell survival was only
slightly increased by the co-culture with MSCs, considering
their lower spontaneous apoptosis rate as compared with B or
NK cells.
In view of producing data for the clinical application of
MSCs in association with HA/TCP, we asked whether the
presence of the biomaterial could affect the immune modula-
tory properties of MSCs of different origin. BM-MSCs, ASCs,
and CB-MSCs were co-cultured with stimulated T, B, and NK
cells in the presence (gray box) or absence (white box) of HA/
TCP scaffold. As shown in Figure 2B, ASCs displayed the
strongest suppressive capabilities on T-cell proliferation, as
compared with BM-MSCs and CB-MSCs. Notably, primed
BM-MSCs (pBM) showed similar inhibitory properties as
resting and primed ASCs (pASC), while inflammatory priming
only slightly increased CB-MSC (pCB) immune modulation.
Resting ASCs, even when associated with the scaffold,
supported B-cell proliferation. In contrast, resting BM-
MSCs and CB-MSCs neither supported nor significantly
inhibited B-cell proliferation. With the exception of CB-
MSCs, all inflammatory-primed MSCs suppressed B-cell
proliferation by more than 50%.
IL-2-mediated NK-cell proliferation was similarly in-
hibited by BM-MSCs, ASCs, and CB-MSCs and this effect
was increased after priming with inflammatory cytokines,
especially for BM-MSCs.
We also investigated the molecular mechanisms under-
lying MSC-mediated immunosuppression. The inhibition of
T-cell proliferation was driven, both in standard culture
setting and in the presence of HA/TCP, by the activation
of indoleamine-2,3 dioxygenase (IDO), as shown by the
addition of its specific inhibitor L-1MT (Fig. 2C). We pre-
viously demonstrated that IDO induction was mostly de-
pendent on IFN-g release by T cells,27 and in agreement,
T-cell inhibition by MSC was partially reversed by IFN-g
blocking antibody; whereas the prostaglandin E2 (PGE2)
specific inhibitor NS-398 had no effect (Fig. 2C). To further
confirm this observation, we quantified the concentration of
tryptophan and kynurenine in culture supernatants, demon-
strating that inflammatory priming led to a similarly strong
activation of IDO regardless of the presence or not of HA/
TCP discs (Fig. 2D).
Overall, HA/TCP biomaterial did not modify the typical
MSC immunological functions and the molecular mecha-
nisms involved.
Osteoblastic differentiation potential of BM-MSCs,
ASCs, and CB-MSCs in presence of HA/TCP discs
We compared the efficacy of two different media, that is,
dexamethasone-based medium (DXM) and BMP-4-based
medium (BMP-4), to induce the osteoblast-like phenotype in
BM-MSCs, ASCs, and CB-MSCs. After 21 days of culture
in osteogenic medium, we found that DXM could induce
distal-less homeobox-5 (DLX5) expression in all MSC types
employed, but triggered only slight mineralization in ASCs
(Figs. 3 and 4A). Conversely, BMP-4 efficiently promoted
calcium nodule deposition in BM-MSCs, CB-MSCs, and, to
a lesser extent, in ASCs.
The analysis of mRNA transcription by RT-qPCR re-
vealed that BM-MSCs were the most prone in activating
osteoblastic-related genes, such as DLX5, parathyroid hor-
mone receptor 1 (PTHR1), osterix (OSX), and osteocalcin
(OSC) (Fig. 4A). As previously demonstrated,12 we con-
firmed that BMP-4 could improve the differentiation of BM-
MSCs. Moreover, BMP-4-based medium could also induce
the transcription of DLX5, PTHR1, and OSX in CB-MSCs
and ASCs. The association of BM-MSCs with HA/TCP
showed a synergistic effect with BMP-4, as demonstrated by
the increase in OSC expression, which encodes a protein
related to the mature osteoblastic phenotype (Fig. 4B). In-
terestingly, culturing BM-MSCs with HA/TCP triggered by
itself the transcription of OSC and OSX genes, without the
need of any differentiation inducers, thus demonstrating
osteo-inductive properties of HA/TCP material (Fig. 4C).
We then performed western blotting analysis of runt-
related transcription factor 2 (RUNX2) expression, one of
the central tissue factors involved in osteogenic differen-
tiation process. As shown in Figure 4D and E, RUNX2 was
detected in BM-MSCs even without any differentiation
stimulus. ASCs expressed low RUNX2 as compared with
BM-MSCs, and in CB-MSCs the expression of RUNX2
was variable among different batches. RUNX2 expression
could be induced at protein level by the treatment with
Table 1. Comparative Analysis of BM-MSCs, ASCs, and CB-MSCs Phenotype After Culture
in Absence or Presence of HA/TCP Discs
BM-MSCs only BM-MSCs+HA/TCP ASCs only ASCs+HA/TCP CB-MSCs only CB-MSCs+HA/TCP
CD54 4.51 – 0.50 2.69 – 0.50 6.3 – 0.59 4.43 – 0.54 9.5– 0.42 9.54 – 0.23
1023.24*6228.40 884.53*6348.20 429.06*6113.03 623.95*6108.05 474.73*624.13 490.51*621.16
CD106 4.22 – 1.15 3.54 – 1.14 1 1 1 – 0.11 1
24.54*63.05 20.20*66.01 7.72*61.57 9.24*60.76 3.53*60.26 3.85*60.31
HLA-ABC 24.86– 2.36 20.49– 2.60 19.96 – 2.44 20.62 – 1.82 3.92 – 0.25 3.92 – 0.20
92.61*631.20 91.26*616.40 42.50*67.30 45.25*65.57 11.08*60.51 12.09*60.95
HLA-DR 1 1 1 1 1 1
58.45*64.60 46.68*625.00 4.09*60.37 3.84*60.41 2.02*60.10 2.02*60.21
MSCs (n = 14) were stimulated or not by IFN-g +TNF-a for 48 h in absence or presence of HA/TCP discs. Cells were collected, stained
with appropriate antibody, and analyzed by flow cytometry. Data were represented as rMFI– SEM of resting MSCs and primed MSCs
(bold). Nonparametric paired Wilcoxon test was used to compare different groups.
*p < 0.05.
BM, bone marrow; CB, cord blood; HA, hydroxyapatite; IFN-g, interferon-g; MSC, mesenchymal stromal cell; rMFI, relative mean
fluorescence intensity; SEM, standard error of the mean; TCP, tricalcium-phosphate; TNF-a, tumor necrosis factor-a.
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FIG. 2. Immune modulatory features of BM-MSCs, ASCs, and CB-MSCs toward different immune effector cells in
presence of HA/TCP scaffold. (A) Immune effector cells (IEC) were co-cultured in absence or presence of BM-MSCs
(n = 5), ASCs (n = 5), and CB-MSCs (n = 4), and seeded in standard culture setting or in presence of HA/TCP. After 4–6
days of co-culture, T, B, and NK cells were collected and stained with anti-CD45-APC and active-caspase-3 antibody-PE.
Percentages of live (clear histograms) and dead (gray histograms) cells were calculated on total CD45 + events. (B) CFSE-
labeled T, B, and NK cells were stimulated and co-cultured with different MSC types (BM, ASC, CB, and interferon-g
(IFN-g)+ tumor necrosis factor-a (TNF-a) treated MSC: pBM, pASC, and pCB) in a standard culture setting and in
combination with HA/TCP discs. After 4–6 days of co-culture, cells were collected and stained with CD45-PerCP and TO-
PRO-3. Percentage of divided cells in absence of MSCs was set as 100% (dotted lines), and each condition was normalized
on this value. Relative proliferation of immune effector cells in co-culture with MSCs of different origins in a standard
culture setting (white box) was analyzed in parallel with the relative proliferation in co-culture with different MSC types in
association with HA/TCP discs (gray box). (C) CFSE-labeled T cells were stimulated and co-cultured with BM-MSCs
(n = 5) in presence of L-1MT, NS-398, and anti-IFN-g blocking antibody in standard culture condition and in presence of
HA/TCP scaffold. After 6 days of co-culture, cells were collected and stained with CD45-PerCP and TO-PRO-3. The
percentage of live T cells that underwent at least one cell division was represented in each condition. Dotted line represented
the mean of divided T cells in absence of MSCs. (D) MSCs (n = 9) were stimulated or not by IFN-g +TNF-a for 48 h in
absence or presence of HA/TCP discs. Culture supernatants were collected for indoleamine-2,3 dioxygenase (IDO) activity
quantification by HPLC. One-way ANOVA test was used to compare different groups. ns p > 0.05; *p< 0.05; **p < 0.01;
and ***p < 0.001.
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DXM or BMP-4 in BM-MSCs and CB-MSCs; while in
ASCs, RUNX2 expression was only slightly upregulated.
Altogether, these data suggest that HA/TCP biomaterial fa-
vored osteogenic commitment of MSCs whatever the differ-
entiation medium, at both transcriptional and protein levels.
Immune modulatory properties of BM-MSCs, ASCs,
and CB-MSCs after osteoblastic differentiation
Considering the superiority of BMP-4 compared with
DXM in promoting osteoblast-like phenotype, we asked
whether the MSC osteogenic commitment, induced by either
HA/TCP or HA/TCP supplemented with BMP-4, could
modulate their immunological properties, thus inducing
immune effector cell activation that could theoretically lead
to implant rejection. For that purpose, we applied our vali-
dated immunological assays to MSCs maintained in the
presence of biomaterial and osteogenic medium for 26 days,
supplemented or not with BMP-4. At the end of differenti-
ation, half of the wells were treated with IFN-g and TNF-a,
as previously described. We found that BM-MSCs, ASCs,
and CB-MSCs associated with HA/TCP or with HA/TCP +
BMP-4 did not induce spontaneous immune cell prolifera-
tion (data not shown) and retained their supportive effects
by preventing spontaneous B- and NK-cell apoptosis (Fig.
5A). Only BMP-4-differentiated CB-MSCs maintained their
inhibitory effect on T- and NK-cell proliferation and, after
inflammatory priming, on B-cell proliferation (Fig. 5B).
Conversely, differentiated ASCs lost their capacity to inhibit
NK-cell proliferation in unprimed conditions, but this po-
tential was restored after inflammatory priming.
The most important differences were found with both
BM-MSCs and BMP-4-differentiated BM-MSCs in associ-
ation with HA/TCP for long-term culture (26 days); in fact,
BM-MSCs lost their capability to inhibit NK-cell prolifer-
ation, even after inflammatory priming, while T-cell pro-
liferation was still inhibited without any further increase
after inflammatory priming. On the other hand, the capa-
bility of IFN-g/TNF-a-primed, BMP-4 differentiated BM-
MSCs to suppress B-cell proliferation was not affected.
IDO activation also maintained its central role in in-
hibiting T-cell proliferation in BMP4-differentiated MSCs.
However, NS-398, the specific inhibitor of cyclooxygenase
2 (COX-2) pathway, partially restored the proliferation of
FIG. 3. Differentiation potential of BM-
MSCs, ASCs, and CB-MSCs in presence of
dexamethasone (DXM) or bone morphoge-
netic protein 4 (BMP-4) in standard culture
conditions. After a 21 day culture in osteo-
genic medium, cells were fixed and stained
for determination of alkaline phosphatase
activity (upper), mineral deposition through
Von Kossa (VK) staining (middle; repre-
sentative image of lipid droplet detection in
ASCs as indicated by the arrow), and cal-
cium nodule formation by means of Alizarin
Red (AR) staining (lower). Images were
acquired by Axiovert Z1 microscope (Zeiss)
at 10· magnification. The representative
images are derived from five different do-
nors for BM-MSCs, five different donors for
ASCs, and four different donors for CB-
MSCs. Color images available online at
www.liebertpub.com/tea
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FIG. 4. Osteoblastic differentiation of BM-MSCs, ASCs, and CB-MSCs with DXM or BMP-4-inducing media in a standard
culture setting and in presence of HA/TCP scaffold. (A) BM-MSCs, ASCs, and CB-MSCs were cultured for 21 days in presence
of osteogenic medium supplemented with dexamethasone or BMP-4. Relative gene expression was represented as fold change
(Y axis) as compared with control condition without inducers. (B) Synergistic effect of HA/TCP discs on osteocalcin (OSC)
expression in BM-MSCs. Y axis represents fold change of OSC gene expression in BM-MSCs+BMP-4 in association with HA/
TCP as compared with BM-MSCs cultured in presence of BMP-4 in a standard culture setting. (C) Osterix and osteocalcin
relative expression in BM-MSCs, ASCs, and CB-MSCs cultured in presence of HA/TCP, as compared with cells cultured in
standard culture conditions, in absence of dexamethasone and BMP-4 addition. (D) Western blotting analysis of runt-related
transcription factor 2 (RUNX2) expression of MSCs cultured in expansion medium, according to each cell factory protocol
(upper panel). Western blotting analysis of RUNX2 protein expression after 21 days of culture in differentiation medium
containing DXM or BMP-4 in BM-MSCs, ASCs, and CB-MSCs. b-actin was used as loading control. (E) Quantification of
RUNX2 expression in expanded MSCs (BM-MSC, n= 3; ASC n= 3; CB-MSC n= 3) and in differentiated MSCs (BM-MSC,
n= 3; ASC n= 3; CB-MSC n= 3). For quantification of RUNX2 expression, relative protein level was normalized to b-actin.
Nonparametric paired Wilcoxon test was used to compare different groups. *p< 0.05 and **p< 0.01.
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FIG. 5. Immune modulatory features of predifferentiated BM-MSCs, ASCs, and CB-MSCs toward different immune effector
cells in presence of HA/TCP scaffold. (A) After differentiation process of MSCs, purified T, B, and NK cells were thawed and
seeded in 24-well plates in presence of undifferentiated or BMP-4-differentiated MSCs. After 4–6 days of co-culture T, B, and
NK cells were collected and stained with anti-CD45-APC and active-caspase-3 antibody-PE. Percentage of live (clear his-
tograms) and dead (gray histograms) cells was calculated in total CD45+ events. (B) CFSE-labeled T, B, and NK cells were
stimulated and co-cultured with undifferentiated and predifferentiated BM-MSCs, ASCs, and CB-MSCs. After 4–6 days of co-
culture, cells were collected and stained with CD45-PerCP and TO-PRO-3. Percentage of dividing cells in absence of MSCs
was set as 100% (dotted lines), and each condition was normalized on this value. Relative proliferation of immune effector cells
in co-culture with undifferentiated MSCs (white box) was analyzed in parallel with the relative proliferation in co-culture with
BMP-4-differentiated MSCs (gray box). The data obtained are represented as relative proliferation of stimulated-T, -B, or -NK
cells in comparison with the control condition (immune effector cells without MSCs). (C) CFSE-labeled T cells were
stimulated and co-cultured with undifferentiated and predifferentiated BM-MSCs in presence of L-1MT and NS-398. After 6
days of co-culture, cells were collected and analyzed by means of flow cytometry. Percentage of dividing cells in absence of
MSCs was set as 100% (dotted lines), and each condition was normalized to this value. The percentage of proliferation of T
cells co-cultured with MSCs in absence of inhibitor was considered as zero. Relative rescue of proliferation was calculated by
comparing the percentage of divided cells with the control. (D) Culture supernatants of differentiated and/or primed BM-MSCs
(n= 5) were collected for IDO activity quantification by HPLC and for prostaglandin E2 (PGE2) quantification by ELISA
assay. One-way ANOVA test was used to compare different groups; *p< 0.05; **p< 0.01; and ***p< 0.001.
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T cells when co-cultured with BMP-4-differentiated BM-
MSCs (Fig. 5C). We then evaluated IDO and COX-2 acti-
vation by measuring kynurenine and PGE2 production in
cell supernatants (Fig. 5D). The differentiation of BM-
MSCs did not alter the capability of IFN-g and TNF-a to
induce IDO activation; however, osteoblastic differentiation
induced by BMP-4 increased PGE2 production and prosta-
glandin-endoperoxide synthase 2 (PTGS2) transcription in
primed BM-MSCs, thus confirming the synergistic role of
COX-2 pathway with IDO in BMP-4-differentiated MSCs
(Fig. 6A).
We then assessed whether inflammatory priming could
affect differentiation and activation state of MSCs. The
treatment with inflammatory cytokines reduced RUNX2
expression at both mRNA (Fig. 6B) and protein levels, in
both DXM- and BMP-4-treated MSCs. Moreover, inflam-
matory priming suppressed the BMP-4-mediated activation
of Smad-1, -5, and -8 and the shift to the TNF-a-related
NF-kB phosphorylation (Fig. 6C). Thereafter, osteogenic
differentiation of BM-MSCs is linked to changes of im-
munoregulatory functions, which are partially restored by
the exposure to the inflammatory milieu.
FIG. 6. IDO1 and prostaglandin-endoperoxide synthase 2 (PTGS2) expression in primed BM-MSCs in control medium or
in presence of BMP-4. (A) BM-MSCs were cultured for 21 days in presence of either osteogenic medium alone or
supplemented with BMP-4. After differentiation process, cells were cultured for 48 h with inflammatory cytokines before
RNA extraction. Relative gene expression is represented (Y axis) using GADPH as a reference gene. (B) Effect of
inflammatory priming on RUNX2 expression in BM-MSCs cultured for 21 days in presence of BMP-4. After differentiation
process, cells were exposed to inflammatory cytokines for 48 h before RNA extraction. Relative gene expression is
represented as fold change (Y axis) as compared with GADPH expression. (C) Western blotting analysis of RUNX2, NF-
kB, phospho-NF-kB, and phospho-Smad-1, -5, and -8 expression in BM-MSCs. After 21 days of induction with either
control medium, DXM-based medium or BMP-4-based medium, cells were lysed and proteins were collected and detected
through sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). b-Actin was used as loading control. One
representative experiment was shown for BM-MSCs. pC = 48 h IFN-g and TNF-a + 21 days control medium; C = 21 days
control medium; Cp = 21 days control medium+ 48 h IFN-g and TNF-a; pD = 48 h IFN-g and TNF-a + 21 days DXM-based
medium; D = 21 days DXM-based medium; Dp= 21 days DXM-based medium + 48 h IFN-g and TNF-a; pB= 48 h IFN-g
and TNF-a + 21 days BMP-4-based medium; B = 21 days BMP-4-based medium; and Bp = 21 days BMP-4-based medi-
um + 48 h IFN-g and TNF-a. Nonparametric paired Wilcoxon test was used to compare different groups. *p< 0.05 and
**p < 0.01.
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Discussion
At least 1 million patients per year need treatment for
skeletal disorders, and many of them are treated with bone
graft substitutes. The current gold standard for bone re-
generation is represented by bone autograft due to its proven
osteogenic properties and the lack of immunological rejec-
tion. However, this technique has important limitations re-
lated to the explant of adequate autologous bone fragments
from iliac crest, with associated morbidity for the pa-
tients.8,33 An alternative chance is represented by BTE,
which is based on the use of bone substitutes as a scaffold10
associated to MSC transplantation. If employed alone, both
approaches have several limitations related to either the
scarce number of residual osteoprogenitor cells34,35 or the
insufficient degree of MSC engraftment and bone forma-
tion,36 respectively. Therefore, the approach combining the
two strategies seems to be more promising.11,12,24 In fact,
the scaffold not only provides mechanical stability but also
acts as a vehicle actively supporting MSC differentiation
into osteoblasts and new bone formation.37,38
Since MSCs of different origins are powerful immune
regulatory cells, and allogeneic MSCs could be theoretically
employed for regenerative medicine in case of lack of au-
tologous cells, it is mandatory to produce preclinical data on
MSC immunological properties in presence of the scaffold,
before moving into the clinical practice. To this aim, we
studied the effect of an HA/TCP scaffold, which has been
recently approved as a filler in bone defects by the European
Community (EC label), on the immune modulatory effects
of MSCs of different origins. We found that the association
of HA/TCP with BM-MSCs, ASCs, or CB-MSCs did not
affect the MSC immunophenotype and immune modulatory
functions. In particular, all the MSC types cultured in
presence of the HA/TCP scaffold promoted the survival of
resting immune effector cells, while inhibiting the prolifer-
ation of activated T and NK cells and, after inflammatory
priming, B cells. These features could favor the bone re-
generation process in vivo by controlling local inflammation
in the injury site, without affecting the survival of quiescent
immune effector cells.
Some recent reports compared the capabilities of BM-
MSCs, ASCs, and CB-MSCs to differentiate into mesoder-
mal tissues, that is, adipocytes, chondrocytes, and osteo-
blasts.39–41 Here, we asked whether BM-MSCs, ASCs, and
CB-MSCs differ in their expression of RUNX2, one of the
pivotal factors driving osteoblast differentiation.42 We
found that BM-MSCs from different donors significantly
expressed RUNX2. In contrast, ASCs expressed low levels
of RUNX2, while its expression was detectable only in 2/4
CB-MSC samples.
RNA and protein expression analysis showed that BM-
MSCs and CB-MSCs possess higher osteogenic differenti-
ation potential as compared with ASCs. Notably, ASCs
could be induced only slightly to become mature osteoblasts
by DXM-based medium, which instead induced adipogenic
differentiation with lipid draft accumulation in 4 out of 5
samples (Fig. 3); this finding could depend on ASC-specific
ontogenesis. In addition, some reports showed that ASCs
might strongly induce new blood vessel formation and
promote bone healing through an indirect mechanism
probably related to pro-angiogenic factors.43 In contrast,
BMP-4 addition induced a huge differentiation in BM-
MSCs and CB-MSCs. ASCs were also induced by BMP-4 to
produce calcium deposition in culture, although less re-
markably. The differences among various cell sources could
be determined by both tissue origin and culture medium
employed for cell expansion. Interestingly, the association
of MSCs with HA/TCP, in absence of any differentiation
stimulus, induced the transcription of osteoblast-related
genes (OSX and OSC) in BM-MSCs and, to a lesser extent,
in ASCs and CB-MSCs, thus confirming the high os-
teoinductivity of HA/TCP on MSCs, as previously shown in
animal models.44–46 The osteoinductive features of HA/TCP
are related to calcium phosphate release, as demonstrated
both in vitro and in vivo by using calcium-deficient HA
materials.47,48
The adequacy of specific animal models to assess whether
allogeneic MSCs may drive new bone formation is still
under debate; for instance, mouse MSCs display several
important differences from human MSCs, including the
immune regulatory mechanisms,49 and the results cannot be
directly transferred into the human setting. The use of hu-
manized animal models, generated by the infusion of allo-
geneic hematopoietic stem cells in immune deficient mice,
may represent a more suitable approach to study the feasi-
bility of MSC therapy in an allogeneic setting.50
To produce preclinical in vitro data on the feasibility to
use allogeneic predifferentiated MSCs in combination with
the scaffold, we investigated whether MSC differentiation in
the presence of HA/TCP scaffold could affect their immune
modulatory properties. ASCs and CB-MSCs retained most
of their regulatory features even after BMP-4-mediated
differentiation, while BMP-4-differentiated BM-MSCs be-
came less suppressive toward T- and NK-cell proliferation.
The latter finding could be related to the higher tendency of
BM-MSCs to differentiate into osteoblasts, which do not
seem to be immune modulatory.51,52 Osteoblastic differen-
tiation of BM-MSCs was also evident after a 26 day culture
with HA/TCP scaffold, in the absence of DXM or BMP-4,
but this partial differentiation was not associated with
the loss of inhibitory potential. The balance between bone-
depositing osteocyte-like MSCs and immunosuppressive
undifferentiated MSCs could be useful, in vivo, to promote
bone healing and to reduce local inflammation.
We then investigated the molecular mechanisms in-
volved in the inhibition of T-cell proliferation by BMP-4-
differentiated MSCs. We found that BMP-4-differentiated
BM-MSCs switched on their suppressive machinery by
activating both IDO and COX-2, whose role was not sig-
nificant in human undifferentiated BM-MSCs. PGE2 is
produced rapidly as a mediator of inflammation after frac-
ture, and recent data highlighted the role of COX-2 in im-
proving fracture healing. In a multiple tibial fracture mouse
model, COX-2 gene therapy increased the number of mes-
enchymal progenitors within the fracture callus, promoted
neoangiogenesis, and improved osteoblastic differentiation
of resident MSCs.53 This phenomenon could also occur in
humans, as COX-2 expression by differentiated BM-MSCs
could promote the differentiation of neighboring MSCs and
trigger the anti-inflammatory effect.
However, fracture healing results from the balance be-
tween pro-inflammatory and anti-inflammatory signals. Many
groups studied the effect of inflammation on the development
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of autoimmune and degenerative diseases associated with
impaired healing.54 Some inflammatory cytokines, such as
IFN-g and TNF-a, may inhibit the differentiation of MSCs
into osteoblasts both in vitro and in vivo55,56; on the other
hand, the suppression of TNF signaling impairs bone healing
in vivo.57 The priming of all MSCs types with IFN-g and
TNF-a before osteoblastic differentiation induced the inhi-
bition of RUNX2 overexpression, unless BMP-4 was used as
an osteoblastic inducer. These data support the concept that
BMP-4 is a better inducer of osteoblastic differentiation of
MSCs as compared with DXM.
Overall, our study gives new clues about MSC biology
and some preclinical data supporting the use of allogeneic
MSCs in combination with ceramic scaffolds to treat bone
defects. The possibility to load the scaffold with bioactive
molecules, such as BMPs or VEGF, is currently under in-
vestigation to increase both bone regeneration and angio-
genesis, preserving a useful degree of anti-inflammatory
effects.
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